VivoSeq
Other

Systemic Inflammatory Response Syndrome

16

Pipeline Programs↗

1

Active Trials↗

11

Companies Involved↗

Systemic Inflammatory Response Syndrome is an emerging landscape with 16 programs across 11 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Incyte, Gilead. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

71/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2M

Milestone Pharmaceuticals Inc.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3T

Tonghua Anrate Biopharmaceutical Co., Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

16 of 18 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody16%Cell therapy16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Terminated2 · 20%
Unknown status2 · 20%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Recruiting·—·Phase 2·NCT04533464·156 enrolled
Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study
Completed·AAustin Health·Phase 2·NCT00706771·70 enrolled
Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome
Completed·—·Phase 4·NCT03876041·60 enrolled
Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)
Completed·AApex Bioscience·Phase 3·NCT00021502·1,000 enrolled
Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
Completed·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 4·NCT00219375·649 enrolled
Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients
Completed·MMedical University of Vienna·Phase 4·NCT00708747·40 enrolled
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
Terminated·—·Phase 3·NCT00529633·16 enrolled
Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis
Terminated·—·Phase 3·NCT01359813·193 enrolled
Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome
Unknown status·HHuashan Hospital·Phase 3·NCT05391789·120 enrolled
Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
Unknown status·MMinia University·Phase 1·NCT05946122·106 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)